Arrowhead reports lower pancreatitis rates, early cholesterol drug results
anatoliycherkas/iStock via Getty Images
Arrowhead Pharmaceuticals (ARWR) said its drug plozasiran reduced rates of acute pancreatitis, a sudden inflammation of the pancreas, by 78% compared with placebo in a pooled analysis of two late-stage studies. The company also reported early results showing an experimental treatment lowered both
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.